VXRT Vaxart Covid-19, Uptrend and Price Target

VXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection.

A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates.

On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections.

On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00

From a technical analysis point of view, the stock looks in an uptrend.